Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7852W HIGH $3.82
Volume
534.39 K
Value Traded
671.24 K
Short % Float
8.87%
-3.85%Week
-13.46%1 Month
-30.56%3 Month
-44.58%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
72.35 M
EPS (TTM)
-0.51
P/E Ratio
-
Ent. Value
-15.69 M
Total Shares
64.28 M
Float Shares
55.66 M
Insiders
8.54%
Institutions
54.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IBIO Catalyst Timeline
Dated clinical, regulatory and corporate events for iBio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for iBio, Inc.
228Total events
4Upcoming
38Tier-1 (high impact)
2010 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲IND ClearanceIBIO-600IND
Regulatory clearance to initiate Phase 1 clinical trial of IBIO-600 in Australia
obesitysource ↗
▲Preclinical PoCIBIO-610Preclinical
New preclinical data from obese NHP study for IBIO-610: visceral fat reduced by 6.7%, total fat mass by 5.2%
obesitysource ↗
▲Pipeline PrioritizationCorporate
Strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) with a selective bispecific antibody
PH-HFpEFsource ↗
▲Runway Guidance UpdateCorporate
Cash runway extended into Q4 fiscal year 2028 via warrant exercises
▲IND ClearanceIBIO-600IND
Regulatory clearance (CTN acknowledgement from TGA and ethics approval from HREC) to initiate Phase 1 trial of IBIO-600 in Australia
overweight and obese adult participantssource ↗
▲First Patient DosedIBIO-600Trial
First participant dosing in Phase 1 clinical trial of IBIO-600
obesitysource ↗
▲Preclinical PoCIBIO-610Preclinical
Preclinical body composition data from obese NHP study showing reduction of 6.7% visceral fat and 5.2% total fat mass
obesitysource ↗
◆IND SubmissionIBIO-600IND
Regulatory submission for IBIO-600 expected in Q1 2026
obesity, muscle preservationsource ↗
▲Trial InitiationIBIO-600Trial
Initiation of Phase 1 clinical trial of IBIO-600
obesity, cardiometabolic and cardiopulmonary diseasessource ↗
▲Development Candidate NominationIBIO-800Preclinical
Selected development candidate for IBIO-800
cardiopulmonary disease, PH-HFpEFsource ↗
▲Partnership / LicenseCorporate
In-licensed AstralBio's amylin receptor antibody program
obesity and metabolic diseasesource ↗
●Preclinical PoCIBIO-610Preclinical
NHP, CMC, and toxicology studies for IBIO-610 initiated
obesitysource ↗
▼Equity OfferingCorporate
Closed underwritten public offering with up to $100 million gross proceeds
▲Preclinical PoCIBIO-610Preclinical
Presented non-human primate data for IBIO-610 showing extended half-life and potential for twice-yearly dosing
obesitysource ↗
◆Oral PresentationIBIO-610Presentation
Oral presentation of IBIO-610 NHP PK data at ObesityWeek 2025
obesitysource ↗
▲Preclinical PoCIBIO-610Preclinical
NHP PK data showing extended half-life of 33.2 days in NHPs and predicted human half-life up to 100 days
obesitysource ↗
▲Preclinical PoCIBIO-610Preclinical
IBIO-610 preclinical data supporting high-quality fat loss with muscle preservation
obesitysource ↗
▲Preclinical PoCIBIO-600Preclinical
IBIO-600 long-acting anti-myostatin antibody preclinical data
cardiometabolic diseasesource ↗
▲Preclinical PoCPreclinical
Bispecific antibody against myostatin and activin A preclinical data
obesitysource ↗
▼Equity OfferingCorporate
Closed warrant inducement transaction with $6.2 million gross proceeds
●Management ChangeCorporate
Kristi Sarno appointed Senior Vice President of Business Development
▼Equity OfferingCorporate
iBio announces proposed underwritten public offering of pre-funded warrants and Series G and H warrants
▲Preclinical PoCIBIO-610Preclinical
IBIO-610 observed to induce fat-selective weight loss in DIO mice
obesitysource ↗
▲Preclinical PoCIBIO-600Preclinical
PK modeling suggests IBIO-600 can be dosed twice-yearly, quarterly, or co-formulated with weekly GLP-1s
muscle wastingsource ↗
▲Preclinical PoCIBIO-600Preclinical
IBIO-600 demonstrates extended half-life in obese NHPs and blocks myostatin in human muscle cells
obesity, cardiometabolic diseasessource ↗
▲Preclinical PoCIBIO-610Preclinical
IBIO-610 induces fat-selective weight loss and synergizes with GLP-1 in DIO mice
obesity, cardiometabolic diseasessource ↗
●Preclinical PoCIBIO-101Preclinical
IBIO-101 in preclinical development for solid tumors
solid tumorssource ↗
◆Poster PresentationPresentation
Presentation of additional preclinical data of Activin E antibody at International BMP Conference
obesitysource ↗
▲Partnership / LicenseCorporate
Licensing of first-in-class antibody targeting Activin E from AstralBio
cardiometabolic diseases and obesitysource ↗
▲Preclinical PoCIBIO-600Preclinical
IBIO-600 NHP PK data shows extended half-life and muscle growth
obesity, muscle preservationsource ↗
▲Preclinical PoCPreclinical
Activin E antibody interim in vivo data shows muscle sparing weight loss
obesitysource ↗
▲Preclinical PoCIBIO-600Preclinical
Promising non-human primate data for IBIO-600
cardiometabolic diseases and obesitysource ↗
▲Partnership / LicenseCorporate
In-licensing of first-in-class Activin E antibody
cardiometabolic diseases and obesitysource ↗
▲Quarterly UpdateCorporate
iBio common stock approved for listing on Nasdaq Capital Market, transfer from NYSE American
Past FDA Catalysts and PDUFA Decisions
How IBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | IBIO-610 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$20M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.3x
rNPV / MCap
Top 55%
Micro Cap(rank 362 of 658)
Percentile Rank
iBio, Inc. faces pipeline headwinds (35/100), with $79M risk-adjusted pipeline value, led by IBIO-600 in Overweight , Obesity (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IBIO-600 Small moleculeNCT07487376 | Overweight , Obesity | Phase 1 | RECRUITING | 32 | May 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every IBIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IBIO-600 | obesity | 2025-04-07 | half life: 57-130 days; lean mass increase low dose: 3.1% (163g); lean mass increase high dose: 5.1% (270g)Read More | iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline Non-human priRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stoner ElizabethDirector | Grant/Award | 60,000 60,000 held | $0.00 | 05/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IBIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0.3 % | 7.01 M | 4.01 M | 28.99% ( 900.68 K) |
IBIO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IBIO ranks across every disease it competes in
Competitive Position is a premium feature
See how IBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIBIO News
IBIOiBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
iBio, Inc. will participate in the 21st Annual Wells Fargo Healthcare Conference from September 8-10, 2026, in Boston. CEO Martin Brenner will engage in a fireside chat on September 8, and the event will be livestreamed. Additionally, one-on-one investor meetings will be available with company executives.
Read more →IBIOiBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio, Inc. reported its fiscal year 2026 financial results, highlighting its transition to a clinical-stage company with the initiation of the Phase 1 trial for IBIO-600. The company also advanced its IBIO-610 program, showing promising preclinical results for obesity treatment. Despite a revenue decrease, iBio secured significant financing to support its clinical pipeline and appointed new leadership to enhance its strategic direction.
Read more →IBIOiBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
iBio, Inc. has appointed Dr. Molly Carr as Chief Medical Officer, enhancing its clinical leadership. Dr. Carr brings over 30 years of experience in endocrinology and metabolic disease, previously holding senior roles at major biopharmaceutical companies. Her leadership is expected to drive iBio's cardiometabolic pipeline towards late-stage development.
Read more →IBIOiBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
iBio, Inc. reported that a single dose of IBIO-610 achieved up to 98% inhibition of active Activin E in an obese non-human primate study, maintaining suppression for eight weeks. The treatment, particularly when combined with semaglutide, showed significant fat loss while preserving lean mass. Full data will be presented at the upcoming EASD Annual Meeting.
Read more →IBIOiBio to Participate in Upcoming Healthcare Investor Conferences
iBio, Inc. will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum. CEO Martin Brenner and CFO Felipe Duran will present and hold one-on-one meetings with investors. These events aim to showcase iBio's innovative therapies for cardiometabolic and obesity-related diseases.
Read more →IBIO▼ -6.9%on this newsshared move
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
iBio has initiated its Phase 1 clinical trial for IBIO-600, a long-acting anti-myostatin monoclonal antibody aimed at supporting muscle preservation in adults with obesity. The trial will evaluate the safety and efficacy of IBIO-600, with 32 participants expected to enroll. This marks a significant milestone for iBio as it transitions into a clinical-stage biotechnology company.
Read more →IBIOiBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update Received regulatory clearance to initiate its phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into
iBio, Inc. reported its financial results for the third quarter of fiscal year 2026, highlighting significant advancements including regulatory clearance for the phase 1 clinical trial of IBIO-600. The company's strategic pipeline expansion into treating pulmonary hypertension associated with heart failure has also been noted. However, iBio reported no revenue during this quarter and an increase in R&D expenses, reflecting both challenges and ongoing investments in its product development. Additionally, promising preclinical data for IBIO-610 was announced, showing effective reductions in fat mass in studies with non-human primates.
Read more →IBIOiBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors San Diego, California /
iBio appointed Dr. Elizabeth Stoner to its Board of Directors, marking a significant step in the company's transition to a clinical-stage biotech firm. Dr. Stoner brings over 35 years of experience in research and development, having held leadership roles in several biotech companies. Her expertise in clinical strategy is anticipated to be crucial as iBio advances its therapies for obesity and pulmonary hypertension. The CEO expressed optimism about Dr. Stoner's contributions during this pivotal time for the company.
Read more →IBIO▲ +6.2%on this news
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and i
iBio has received regulatory approval to initiate a Phase 1 clinical trial of IBIO-600, a monoclonal antibody aimed at preserving muscle and improving body composition. The trial will begin dosing participants in the second quarter of 2026, marking a significant milestone for the company as it advances to clinical stages. The study, randomized and placebo-controlled, aims to evaluate safety and pharmacokinetics in overweight and obese adults. Previous studies have shown promising results in terms of muscle preservation and body composition improvements.
Read more →IBIOiBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
iBio, Inc. announced a corporate update call scheduled for March 17, 2026, to discuss its strategic expansion into therapies for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company is developing a bispecific antibody aimed at addressing multiple drivers of the disease. iBio's CEO emphasized the potential of this approach to meet significant unmet medical needs in the cardiometabolic space.
Read more →IBIOiBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss Study demonstrated reduction of 6.7% visceral fat and
iBio, Inc. has announced promising preclinical data revealing IBIO-610's potential as a first-in-class therapy for fat-selective weight loss in obese non-human primates. The study indicated a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass, achieved while maintaining lean mass. These findings, supported by previously observed effects in rodents, strengthen the case for IBIO-610's continued development targeting obesity and related diseases. The complete analysis of data will be presented at scientific conferences throughout 2026.
Read more →IBIO▼ -5.8%on this news
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed
iBio, Inc. has reported its Q2 fiscal year 2026 financial results, revealing no revenue but securing $26 million in PIPE financing to enhance its pipeline programs. The funding will aid in the advancement of IBIO-610 and IBIO-600 towards human clinical trials and extends the company's cash runway into fiscal year 2028. Additionally, iBio noted increased research and development costs due to escalating operational expenditures. Despite these challenges, the company continues to make progress with new preclinical data and presentations at industry conferences.
Read more →IBIO▲ +14.9%on this news
iBio Announces $26 Million Private Placement
iBio, Inc. announced a $26 million private placement financing agreement with high-quality institutional investors. The proceeds will help advance its preclinical cardiometabolic programs and support other pipeline assets until 2028. The offering is set to close around January 13, 2026, and involves the sale of over 11 million shares at $2.35 each. While the financing is a positive step for iBio, there are risks associated with the inability to sell unregistered shares and potential market fluctuations.
Read more →IBIOiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with
iBio, Inc. announced its first fiscal quarter 2026 financial results and provided a corporate update, highlighting a robust cash position bolstered by a public offering that could yield up to $100 million in gross proceeds. The presentation of new non-human primate data for the Activin E antibody, IBIO-610, indicates the potential for infrequent dosing while enhancing patient compliance. These developments are part of iBio's ongoing strategy to create next-generation therapies aimed at obesity and cardiometabolic diseases, confirming their commitment to innovation in drug development.
Read more →IBIOiBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance Previously reported data showed that in a diet-induced obe
iBio, Inc. has revealed new preclinical data showing the potential of IBIO-610, an Activin E antibody, in fat-selective weight loss and weight maintenance. The study conducted on non-human primates suggests a human half-life of up to 100 days, indicating that treatment could be administered only twice a year. This extended half-life, combined with a unique mechanism of action, positions IBIO-610 as a potential leading therapy for obesity and cardiometabolic diseases, particularly for patients transitioning off GLP-1 therapies.
Read more →IBIOiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update San Diego, California /
iBio, Inc. reported its financial results for fiscal year 2025, highlighting a transformative year with advancements in its pipeline for cardiometabolic diseases and obesity. The company showcased promising data for its antibody candidates IBIO-610 and IBIO-600, alongside securing additional funding to support ongoing research. Despite an increase in operating losses and R&D expenditures, iBio's successful transition to Nasdaq and strategic corporate developments position it for growth. Overall, the firm remains focused on delivering transformative therapies while enhancing shareholder value.
Read more →IBIOBreakthrough Antibodies for Obesity and Cardiometabolic Diseases Corporate Presentation August 2025 Certain statements in this presentation constitute "forward -looking statements" within the meaning of the Private Secur
iBio is making strides in developing innovative therapies for obesity and cardiometabolic diseases, particularly with its antibodies IBIO-610 and IBIO-600. The company's AI-driven technology aims to optimize the discovery of challenging drug targets, potentially improving weight loss while preserving muscle mass. Key financial highlights indicate sufficient resources for ongoing research, with promising pharmacokinetic data supporting infrequent dosing regimens for its lead product. Overall, iBio’s differentiated approach may position it favorably in the competitive biopharma landscape.
Read more →IBIOiBio Announces Proposed Public Offering
iBio, Inc. has announced a proposed public offering that includes pre-funded warrants and Series G and H warrants to purchase its common stock. The proceeds from this offering are intended to support the advancement of its cardiometabolic programs and other pipeline assets. While this decision may enhance iBio's financial position, the completion of the offering is contingent on market conditions and other factors, creating potential risks. The company employs innovative AI-driven approaches in its research and development efforts in biopharmaceuticals.
Read more →IBIOBreakthrough Antibodies for Obesity and Cardiometabolic Diseases Corporate Presentation June 2025 Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securiti
iBio's recent corporate presentation highlighted its differentiated pipeline focused on addressing obesity and cardiometabolic diseases through innovative antibody development. The company showcased its AI-driven discovery technology, which aims to expedite the creation of highly developable pre-clinical candidates. Financially, iBio reported $10.5 million in cash, positioning it well for upcoming initiatives. The presentation also underscored its immuno-oncology pipeline, which incorporates advanced mechanisms to improve safety and efficacy.
Read more →IBIOiBio Reports Fiscal Third Quarter 2025 Financial Results
iBio, Inc. reported its financial results for Q3 2025, highlighting significant progress in its pipeline and a recent $6.2 million equity raise following its move to Nasdaq. The company expressed optimism about the potential of IBIO-600 and a newly in-licensed Activin E antibody to address cardiometabolic diseases and obesity. However, they caution that forward-looking statements may not come to fruition due to various risks, including the timeline for regulatory submissions.
Read more →About iBio, Inc.
Headquarters600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
BIOPHARMAWATCH ELITE PLUS
Trade the next IBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime